- Users of research expertise:
Dr. Maya Berg (PhD, PharmD) ITM
Maya Berg holds a master in Pharmaceutical Sciences (Drug Research and Development, UA, 2004) and a Master after Master in Industrial Pharmacy (UA, 2005) during which she spent a research stay abroad at the ‘Laboratoire de Biologie Fonctionnelle des protozoaires, Muséum National d'Histoire Naturelle’ in Paris to investigate the mode of action of antimalarial R&D compounds with proteomics. Afterwards, Maya started her PhD research as FWO research fellow in the Medicinal Chemistry lab of Prof. K. Augustyns (UA) and successfully designed and synthesized more than 50 hit and lead drug compounds for the treatment of sleeping sickness. In 2007 she returned to the Laboratoire de Biologie Fonctionnelle des protozoaires in Paris with an INSERM fellowship to validate the purine salvage pathway in Trypanosoma brucei as a drug target with RNA interference.
In 2010, Maya joined the Molecular Parasitology Unit (MPU) of Prof. J.C. Dujardin at ITM, where she now coordinates a metabolomics research line to study the biochemical alterations linked to drug resistance in Leishmania donovani, the causative agent of the neglected disease visceral leishmaniasis. In 2011, Maya became a post-doc laureate of the InBev-Baillet Latour foundation. She is also actively involved in other omics research lines within MPU (genomics, transcriptomics, proteomics) in the framework of a systems biology approach to unravel questions related to differentiation and drug resistance in L. donovani. Recently, a systems biology package was developed to characterize induced drug-resistant Leishmania parasites within MPU, paving the way for collaborations with the anti-protozoa drug R&D sector.